乌鸦传媒

A new memory-loss syndrome that mimics the clinical features of Alzheimer's disease was identified, researchers said.

"We propose a set of clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome [LANS] that is highly associated with limbic-predominant age-related TDP-43 encephalopathy [LATE] but also other pathologic entities," wrote David Jones, MD, of the Mayo Clinic in Rochester, Minnesota, and co-authors in .

LATE -- also known as LATE-NC (neuropathological change) -- is a TDP-43 proteinopathy defined in 2019 based on autopsy findings and molecular characteristics of brain tissue.

"LANS and LATE are related, but not identical," Jones said. "Most patients with LANS have LATE, but some patients with LANS may have Alzheimer's disease or other causes of memory impairment," he told 乌鸦传媒.

"LANS can be diagnosed in living patients, while LATE can only be confirmed after death," Jones noted.

Tau-negative neurodegenerative disorders like LANS can , but occur later in life. Unlike Alzheimer's, LANS symptoms are restricted to memory loss and don't involve other cognitive domains.

"In our clinical work, we see patients whose memory symptoms appear to mimic Alzheimer's disease, but when you look at their brain imaging or biomarkers, it's clear they don't have Alzheimer's," Jones said.

"Until now, there has not been a specific medical diagnosis to point to, but now we can offer them some answers," he added. "This research creates a precise framework that other medical professionals can use to care for their patients. It has major implications for treatment decisions, including amyloid-lowering drugs and new clinical trials, and counseling on prognosis, genetics, and other factors."

The proposed criteria incorporate features like older age at evaluation (generally, age 75 and older), mild clinical syndrome, disproportionate hippocampal atrophy, impaired semantic memory, limbic hypometabolism, the absence of neocortical degeneration, and a low likelihood of neocortical tau.

Jones and colleagues applied their criteria to 218 autopsied patients with an antemortem predominant amnestic syndrome in two cohorts -- 165 patients from the and cohort and 53 from the (ADNI) cohort -- who had Alzheimer's neuropathological change, LATE-NC, or both pathologies at autopsy.

The neuropathology-defined groups accounted for 35%, 37%, and 4% of cases in the Mayo cohort, respectively, and 30%, 22%, and 9% of cases in the ADNI cohort. The criteria effectively categorized these cases, with Alzheimer's disease having the lowest likelihoods of LANS, LATE having the highest likelihoods, and both pathologies having intermediate likelihoods. In the Mayo cohort, age at death for those with Alzheimer's neuropathological change was 82.4 years; for those with LATE-NC, it was 91.6 years.

Patients with high likelihoods had a milder, slower clinical course and more severe temporo-limbic degeneration compared with those who had low likelihoods. Stratifying patients with both Alzheimer's neuropathological change and LATE-NC from the Mayo cohort according to their likelihoods showed that those with higher likelihoods had more temporo-limbic degeneration and a slower rate of decline, while those with lower likelihoods had more lateral temporo-parietal degeneration and a faster rate of decline.

"It is important to reiterate that while LANS is highly associated with LATE-NC, it can be associated with other pathologic entities that selectively target the limbic system," Jones and co-authors emphasized.

"One example that can be a potential source of clinical conundrums is the limbic variant Alzheimer's disease, where tau predominantly localizes to the limbic system and therefore qualifies for LANS," they pointed out. "In this scenario, the advanced LANS criteria in combination with visual assessment of tau-PET can help in determining which pathology has the highest likelihood of driving clinical symptoms."

The low number of people with LATE-NC in the study is a limitation, the researchers acknowledged.

"Prospective studies are required to further assess the value of the LANS criteria in predicting underlying pathologies predominantly driving limbic versus neocortical degeneration," they wrote. "This study is retrospective in nature. The implementation of the LANS criteria in clinical settings and prospective studies are needed to further validate and refine this set of criteria."

Comment